GlaxoSmithKline, Fondazione Telethon and Fondazione San Raffaele have entered into a strategic alliance to research and develop novel treatments for rare genetic disorders.
The collaboration will build upon research carried out at the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), a partnership between Fondazione Telethon and Fondazione San Raffaele, using gene therapy carried out on stem cells derived from a patients’ bone marrow.
Under the agreement, GlaxoSmithKline will have an exclusive licence to develop and commercialise an investigational gene therapy for ADA Severe Combined Immune Deficiency.
GlaxoSmithKline will also co-develop six further applications of ex vivo stem cell therapy for the treatment of a range of rare disorders with its new partners, with the help of a new gene transfer technology developed by HSR-TIGET scientists,.
The companies will develop treatments for disorders including metachromatic leukodystrophy, Wiskott-Aldrich syndrome, beta-thalassemia, mucopolysaccharoidosis type I, globoid leukodystrophy and chronic granulomatous disorder.
Clinical trials for metachromatic leukodystrophy and Wiskott-Aldrich syndrome treatments have been initiated at HSR-TIGET, and are currently enrolling patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataFondazione Telethon will receive an upfront payment of €10m ($13m) from GlaxoSmithKline and is eligible to receive further payments depending on successful completion of a number of predetermined development milestones.
